Pipeline Watch: 11 Approvals And Seven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Image
• Source: Alamy

The table above records the past week's major catalyst events that occurred in the late-stage pipeline during the past week (see table for relevant dates), created using Citeline’s Biomedtracker.

More from Pipeline Watch

More from R&D

High-Dose Semaglutide Data A Mixed Bag For Novo Nordisk

 
• By 

Semaglutide 7.2mg bests placebo for weight loss at 72 weeks, but with efficacy lower than seen with Novo Nordisk’s CagriSema or Lilly’s Zepbound.

Boehringer’s Three Shots At Schizophrenia Miss The Target

 

Three parallel Phase III studies of iclepertin aiming to improve cognitive function have failed but optimism about other schizophrenia treatments is growing.

Acepodia Plays Dual-Payload Ace To Join Global ADC Race

 

Acepodia’s dual-payload antibody-drug conjugates can link multiple tumor-killing agents without antibody modification. Apart from a GPC3-targeting candidate, the Taiwan-US biotech is also working on a bispecific antibody ADC with two different payloads, its CEO tells Scrip in an interview.